Medscape is available in 5 Language Editions – Choose your Edition here.


Holocarboxylase Synthetase Deficiency

  • Author: Karl S Roth, MD; Chief Editor: Luis O Rohena, MD  more...
Updated: Nov 03, 2015


Holocarboxylase synthetase (HCS) deficiency was defined as a distinct genetic disorder several years after its initial clinical description, similar to the discovery of propionic acidemia. From 1970-1973, only 3 clinically varied cases of children who excreted beta-methylcrotonic acid in their urine were reported. Notable differences included the age at presentation (neonatal to 9 mo), presence of acidosis, and response to biotin administration.

In 1976, Roth et al reported an infant who was the second affected sibling born to an otherwise healthy mother. The first child, a male, died from aspiration and severe acidosis 36 hours after birth; no autopsy or other information was available. From birth, the second child was clinically affected by an unrelenting metabolic acidosis and a massive excretion of beta-methylcrotonic acid, lactic acid, beta-hydroxybutyric acid, and beta-hydroxypropionic acid. This child died 105 hours postdelivery after little improvement from small intravenous doses of megavitamins, including biotin.[1] Subsequent studies using fibroblasts recovered from the infant demonstrated a defect of carbon dioxide fixation into pyruvate, propionate, and beta-methylcrotonate; thus, the term multiple carboxylase deficiency was applied to the disorder.

Recognizing the unlikely coexistence of 3 gene mutations in a single individual, research continued in an attempt to find a unifying factor to explain the involvement of 3 distinct enzymes. Patients seemed to respond to biotin administration, and each affected enzyme required biotin as a cofactor. This directed attention toward the work of Lynen, who had previously demonstrated that carbon dioxide fixation in microbes required covalent attachment of the biotin to an apoprotein. Since covalent bond formation requires the mediation of an enzyme, a search began for an enzyme deficiency that was common to all 3 carboxylases and that might explain the defective function of each.

Finally, in 1980, based on the work of Saunders and coworkers, Roth et al reported holocarboxylase synthetase deficiency in a subsequent sibling of their original case; the sibling had an excellent clinical response to biotin administration in pharmacologic doses.[2, 3] In 1981, Burri et al reported evidence of holocarboxylase synthetase deficiency in this patient and in others with a similar neonatal presentation; thus, the nature of the defect was redefined as a single enzyme defect.[4] The late or juvenile-onset type of presentation, which resembled the newly defined neonatal holocarboxylase synthetase deficiency in virtually all respects other than age at onset, still required an explanation.

In 1983, Wolf et al suggested that the late-onset type may be due to a defect in biotin recycling rather than to defective absorption; others had proposed the same finding.[5] Recycling is well described for other vitamins, helping explain the normally miniscule daily requirements. Logically, the same should hold true for biotin.

The major contribution of Wolf et al was in demonstrating the presence of the enzyme human biotinidase and its role in biotin recycling. Late-onset multiple carboxylase deficiency is now known to be due to a biotinidase deficiency and subsequent impairment of biotin recycling. Thus, what was originally reported as the disease beta-methylcrotonic aciduria has been separated into 3 distinct genetic disorders: beta-methylcrotonyl-coenzyme A (CoA) carboxylase deficiency, holocarboxylase synthetase deficiency, and biotinidase deficiency. This article focuses on the specific defect recognized as holocarboxylase synthetase deficiency.



Carbon dioxide fixation, a process typically associated with plant metabolism, is a vital reaction in humans. In individuals with multiple carboxylase deficiency, more than 3 metabolic pathways are impaired. Carbon dioxide fixation occurs in the metabolism of several different substrates; thus, several pathways are involved in the defect. Acetyl-CoA carboxylase (ACC) is key to fatty acid synthesis, pyruvate carboxylase is a critical step in gluconeogenesis, propionyl-CoA carboxylase produces methylmalonyl-CoA prior to the ultimate formation of succinyl-CoA, and beta-methylcrotonyl-CoA carboxylase is critical in the degradation of leucine for energy. Thus, affected infants have increased levels of circulating odd-chain fatty acids (due to deficient propionyl-CoA carboxylase), hypoglycemia (deficient pyruvate carboxylase), and ketoacidosis (deficient propionyl-CoA carboxylase and beta-methylcrotonyl-CoA carboxylase).[6]

As in all other enzyme reactions that require a cofactor, normal production of each of the carboxylase apoproteins is insufficient to carry out their individual carbon dioxide–fixation reactions. Since all enzyme function requires binding between the substrate and enzyme, impairment of such binding prevents enzyme function. In apocarboxylases, the binding of each to carbon dioxide requires the presence of biotin, to which the carbon dioxide physically attaches.

For a carboxylase protein to function normally, a covalent bond with the cofactor biotin must be established. Because covalency involves a great deal of bond energy, such bonds require enzyme-mediated reactions before they can occur efficiently. The specific function of holocarboxylase synthetase is to establish a covalent bond between a lysine residue in the apocarboxylase molecule and a biotin molecule.[7]

Therefore, holocarboxylase synthetase deficiency impairs all carbon dioxide–fixation reactions within the cell. These include reactions mediated by acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and beta-methylcrotonyl-CoA carboxylase. Each of these serves an extremely important cellular function, and impairment has significant adverse consequences that manifest as clinical disease. A recent study reported that the liver and brain have different mechanisms of holocarboxylase synthetase gene regulation, suggesting that brain function is conserved at the expense of somatic cell function in biotin deficiency.

A study of holocarboxylase synthetase messenger RNA (mRNA) from 3 different human cell lines suggests the existence of 3 distinct types of mRNA originating from separate exons. Thus, many holocarboxylase synthetase mutations may remain undetected. A separate report of a partially responsive patient given extraordinarily high doses of biotin may represent one such example.

Acetyl-CoA carboxylase has an important cellular function as the first step in fatty acid synthesis. The 3-carbon fatty acyl compound malonyl-CoA is formed through carboxylation of acetyl-CoA. Regulation of acetyl-CoA carboxylase activity is important to the energy economy of the cell, since excess glucose is normally converted to lipid through this reaction. Although no individual symptomatology may be directly attributed to functional impairment, lactate accumulation in infants with holocarboxylase synthetase deficiency may be partially attributable to the inability to channel acetyl-CoA (produced from glucose oxidation) into fatty acid synthesis.

Pyruvate carboxylase is a major step in the process of gluconeogenesis, a sequence of reactions that results in resynthesis of a 6-carbon glucose molecule from two 3-carbon fragments produced chiefly from glycolysis. Interruption of gluconeogenesis is likely to result in clinical hypoglycemia; this is a well-known finding in both isolated pyruvate carboxylase deficiency and holocarboxylase synthetase deficiency. In addition, hypoglycemia encourages oxidation of fatty acids, including essential fatty acids, resulting in the development of a typical exfoliative dermatitis.

The substrates for both propionyl-CoA and beta-methylcrotonyl-CoA carboxylases are organic acids that contain an alpha-keto group; failure to fix carbon dioxide through these 2 enzyme reactions results in accumulation of keto-acids and clinical ketoacidosis, accompanied by hyperglycinemia and hyperammonemia.

In general, the organic acids inhibit the urea cycle, which diminishes incorporation of free ammonia. This effect is exerted at the site of N -acetylglutamate synthetase (NAGS), which mediates production of the activating substance (N -acetylglutamate [NAG]) for carbamyl phosphate synthetase, the first step in the urea cycle. Diminished activation slows ammonia incorporation, with accumulation in blood and other tissues. See the image below.

Urea cycle. Compounds that comprise the urea cycle Urea cycle. Compounds that comprise the urea cycle are numbered sequentially, beginning with carbamyl phosphate. At the first step (1), the first waste nitrogen is incorporated into the cycle; also at this step, N-acetylglutamate exerts its regulatory control on the mediating enzyme, carbamyl phosphate synthetase (CPS). Compound 2 is citrulline, the product of condensation between carbamyl phosphate (1) and ornithine (8); the mediating enzyme is ornithine transcarbamylase. Compound 3 is aspartic acid, which is combined with citrulline to form argininosuccinic acid (4); the reaction is mediated by argininosuccinate (ASA) synthetase. Compound 5 is fumaric acid generated in the reaction that converts ASA to arginine (6), which is mediated by ASA lyase.

Thus, the major clinical findings in individuals with holocarboxylase synthetase deficiency, described in detail by Roth and coworkers, include severe ketoacidosis, exfoliative dermatitis, and hypoglycemia.[3] The urine may have a distinctive tomcatlike odor; however, the odiferous constituent has not been characterized.




United States

The true incidence in the newborn population cannot be cited for lack of data based on population screening. Holocarboxylase synthetase deficiency is among the rarest of inborn errors, with an estimated incidence of less than 1 per 200,000 live births.


Without early diagnosis and treatment, the mortality rate is close to 100%.[8] With treatment, morbidity depends on the length of delay in diagnosis and the extent of damage incurred from severe acidosis and circulatory shock .


Because the disease is transmitted as an autosomal recessive trait, the male-to-female incidence is equivalent.


Clinical onset occurs shortly (within hours) after birth. Maternal ingestion of biotin supplements during pregnancy may alter the time of presentation by days or weeks.

Contributor Information and Disclosures

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Margaret M McGovern, MD, PhD Professor and Chair of Pediatrics, Stony Brook University School of Medicine

Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Chief Editor

Luis O Rohena, MD Chief, Medical Genetics, San Antonio Military Medical Center; Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Assistant Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Additional Contributors

Christian J Renner, MD Consulting Staff, Department of Pediatrics, University Hospital for Children and Adolescents, Erlangen, Germany

Disclosure: Nothing to disclose.

  1. Roth K, Cohn R, Yandrasitz J, Preti G, Dodd P, Segal S. Beta-methylcrotonic aciduria associated with lactic acidosis. J Pediatr. 1976 Feb. 88(2):229-35. [Medline].

  2. Saunders M, Sweetman L, Robinson B, Roth K, Cohn R, Gravel RA. Biotin-response organicaciduria. Multiple carboxylase defects and complementation studies with propionicacidemia in cultured fibroblasts. J Clin Invest. 1979 Dec. 64(6):1695-702. [Medline].

  3. Roth KS, Yang W, Foremann JW, Rothman R, Segal S. Holocarboxylase synthetase deficiency: a biotin-responsive organic acidemia. J Pediatr. 1980 May. 96(5):845-9. [Medline].

  4. Burri BJ, Sweetman L, Nyhan WL. Mutant holocarboxylase synthetase: evidence for the enzyme defect in early infantile biotin-responsive multiple carboxylase deficiency. J Clin Invest. 1981 Dec. 68(6):1491-5. [Medline].

  5. Wolf B, Grier RE, Parker WD Jr, Goodman SI, Allen RJ. Deficient biotinidase activity in late-onset multiple carboxylase deficiency. N Engl J Med. 1983 Jan 20. 308(3):161. [Medline].

  6. Tammachote R, Janklat S, Tongkobpetch S, Suphapeetiporn K, Shotelersuk V. Holocarboxylase synthetase deficiency: novel clinical and molecular findings. Clin Genet. 2010 Jul. 78(1):88-93. [Medline].

  7. Zempleni J, Li Y, Xue J, Cordonier EL. The role of holocarboxylase synthetase in genome stability is mediated partly by epigenomic synergies between methylation and biotinylation events. Epigenetics. 2011 Jul. 6(7):892-4. [Medline]. [Full Text].

  8. Bailey LM, Ivanov RA, Jitrapakdee S, Wilson CJ, Wallace JC, Polyak SW. Reduced half-life of holocarboxylase synthetase from patients with severe multiple carboxylase deficiency. Hum Mutat. 2008 Jun. 29(6):E47-57. [Medline].

  9. Mayende L, Swift RD, Bailey LM, et al. A novel molecular mechanism to explain biotin-unresponsive holocarboxylase synthetase deficiency. J Mol Med (Berl). 2012 Jan. 90(1):81-8. [Medline].

  10. Slavin TP, Zaidi SJ, Neal C, Nishikawa B, Seaver LH. Clinical Presentation and Positive Outcome of Two Siblings with Holocarboxylase Synthetase Deficiency Caused by a Homozygous L216R Mutation. JIMD Rep. 2013 Sep 13. [Medline].

  11. [Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. 2004 Sep. 114(3):889-94. [Medline]. [Full Text].

  12. De Castro M, Zand DJ, Lichter-Konecki U, Kirmse B. Severe neonatal holocarboxylase synthetase deficiency in west african siblings. JIMD Rep. 2015. 20:1-4. [Medline].

  13. Wilson CJ, Myer M, Darlow BA, Stanley T, Thomson G, Baumgartner ER, et al. Severe holocarboxylase synthetase deficiency with incomplete biotin responsiveness resulting in antenatal insult in samoan neonates. J Pediatr. 2005 Jul. 147(1):115-8. [Medline].

  14. Eldjarn L, Jellum E, Stokke O, Pande H, Waaler PE. Beta-hydroxyisovaleric aciduria and beta-methylcrotonylglycinuria: a new inborn error of metabolism. Lancet. 1970 Sep 5. 2(7671):521-2. [Medline].

  15. Gompertz D, Draffan GH, Watts JL, Hull D. Biotin-responsive beta-methylcrotonylglycinuria. Lancet. 1971 Jul 3. 2(7714):22-4. [Medline].

  16. Gompertz D, Goodey PA, Bartlett K. Evidence for the enzymic defect in beta-methylcrotonylglycinuria. FEBS Lett. 1973 May 15. 32(1):13-4. [Medline].

  17. Malvagia S, Morrone A, Pasquini E, Funghini S, la Marca G, Zammarchi E, et al. First prenatal molecular diagnosis in a family with holocarboxylase synthetase deficiency. Prenat Diagn. 2005 Dec. 25(12):1117-9. [Medline].

  18. Nyhan WL, Willis M, Barshop BA, Gangoiti J. Positive newborn screen in the biochemically normal infant of a mother with treated holocarboxylase synthetase deficiency. J Inherit Metab Dis. 2009 Apr 11. [Medline].

  19. Pacheco-Alvarez D, Solorzano-Vargas RS, Gravel RA, Cervantes-Roldan R, Velazquez A, Leon-Del-Río A. Paradoxical regulation of biotin utilization in brain and liver and implications for inherited multiple carboxylase deficiency. J Biol Chem. 2004 Dec 10. 279(50):52312-8. [Medline].

  20. Santer R, Muhle H, Suormala T, Baumgartner ER, Duran M, Yang X, et al. Partial response to biotin therapy in a patient with holocarboxylase synthetase deficiency: clinical, biochemical, and molecular genetic aspects. Mol Genet Metab. 2003 Jul. 79(3):160-6. [Medline].

  21. Suormala T, Fowler B, Duran M, Burtscher A, Fuchshuber A, Tratzmüller R, et al. Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of responsiveness to biotin therapy in vivo and comparative biochemical studies in vitro. Pediatr Res. 1997 May. 41(5):666-73. [Medline].

  22. Yang X, Aoki Y, Li X, Sakamoto O, Hiratsuka M, Kure S, et al. Structure of human holocarboxylase synthetase gene and mutation spectrum of holocarboxylase synthetase deficiency. Hum Genet. 2001 Nov. 109(5):526-34. [Medline].

Urea cycle. Compounds that comprise the urea cycle are numbered sequentially, beginning with carbamyl phosphate. At the first step (1), the first waste nitrogen is incorporated into the cycle; also at this step, N-acetylglutamate exerts its regulatory control on the mediating enzyme, carbamyl phosphate synthetase (CPS). Compound 2 is citrulline, the product of condensation between carbamyl phosphate (1) and ornithine (8); the mediating enzyme is ornithine transcarbamylase. Compound 3 is aspartic acid, which is combined with citrulline to form argininosuccinic acid (4); the reaction is mediated by argininosuccinate (ASA) synthetase. Compound 5 is fumaric acid generated in the reaction that converts ASA to arginine (6), which is mediated by ASA lyase.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.